Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2021-03-16 Annual Report
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2020
2021-03-16 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the three and twelve months ended December 31, 2020. The document itself is short (3751 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2021-03-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically details an amendment and restatement of the company's bylaws, which is a governance-related change. There is no financial data or earnings information, nor is it an annual or quarterly report. The document is not a report publication announcement but the actual filing of the event. The amendment to bylaws relates to governance structure, so the most appropriate classification is Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like MANG (management changes) or CGR (governance information report). The document length is under 5,000 characters, but it contains the full text of the amendment summary and the filing itself, not just a notice of publication. Therefore, the best fit is RNS with high confidence.
2021-03-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-03-02 English
AMENDMENT TO FORM SC 13G
Major Shareholding Notification
2021-02-16 English
SC 13G
Major Shareholding Notification
2021-02-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.